黄连素联合阿托伐他汀对急性脑梗死患者治疗作用的研究

发布时间：2018-12-12 02:41

【摘要】：目的:探讨黄连素联合阿托伐他汀对急性脑梗死(ACI)患者血清炎症因子(MIF、IL-6、CRP)水平及短期临床预后的作用。方法:选择120例ACI患者,随机分为联合组(n=60)和阿托伐他汀组(n=60)。两组均给予ACI常规治疗。联合组给予黄连素(300 mg tid)+阿托伐他汀(40 mg qd),阿托伐他汀组仅给予阿托伐他汀(40 mg qd)。测定所有患者的血清MIF、IL-6、CRP水平(入院第1、14天)及进行神经功能缺损评分(入院第1、14、90天)。结果:入院第1天及第14天,两组患者血清MIF、IL-6、CRP水平与NIHSS评分呈正相关(P0.05);入院第1天,两组间患者的MIF、IL-6、CRP水平及NIHSS评分比较均无统计学意义(P0.05);入院第14天较第1天,两组患者的血清MIF、IL-6、CRP水平及NIHSS评分均显著降低(P0.05);入院第14天,联合组较阿托伐他汀组血清MIF、IL-6、CRP水平及NIHSS评分显著降低(P0.05);随访第90天,联合组较阿托伐他汀组m RS评分显著偏低(P0.05),短期预后良好率显著偏高(P0.05)。结论:对急性脑梗死的治疗,黄连素联合阿托伐他汀治疗可显著降低ACI急性期血清炎症因子MIF、IL-6、CRP水平,并显著促进神经功能恢复,改善短期预后。
[Abstract]:Objective: to investigate the effect of berberine combined with Atto vastatin on serum inflammatory factor (MIF,IL-6,CRP) levels and short-term clinical prognosis in patients with acute cerebral infarction (ACI). Methods: 120 patients with ACI were randomly divided into two groups: combined group (n = 60) and Atto group (n = 60). Both groups were given ACI routine therapy. The combined group was treated with berberine (300 mg tid) Atto vastatin) (40 mg qd), Atto vastatin group) and only Atto vastatin group (40 mg qd).) The serum MIF,IL-6,CRP level (14 days after admission) and neurological impairment score (1490 days after admission) were measured in all patients. Results: the serum MIF,IL-6,CRP level was positively correlated with the NIHSS score on the 1st and 14th day after admission (P0.05). On the first day of admission, there was no significant difference in MIF,IL-6,CRP level and NIHSS score between the two groups (P0.05). On the 14th day after admission, the serum MIF,IL-6,CRP level and NIHSS score of the two groups were significantly lower than that on the first day (P0.05). On the 14th day after admission, the serum MIF,IL-6,CRP level and NIHSS score in the combined group were significantly lower than those in the Atto vastatin group (P0.05). On the 90th day of follow-up, the m RS score of the combined group was significantly lower than that of the Atto vastatin group (P0.05), and the short-term good prognosis rate was significantly higher (P0.05). Conclusion: in the treatment of acute cerebral infarction, berberine combined with Atto vastatin can significantly reduce the level of serum inflammatory factor MIF,IL-6,CRP in acute phase of ACI, promote the recovery of nerve function and improve the short-term prognosis.
【作者单位】：保定市第一中心医院神经内三科;
【基金】：保定市科技局技术支撑项目(zf15015)
【分类号】：R743.33

【相似文献】